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Abstract: Celiac disease patients may suffer from a number of extra-intestinal diseases related to
long-term gluten ingestion. The diagnosis of celiac disease is based on the presence of a manifest
small intestinal mucosal lesion. Individuals with a normal biopsy but an increased risk of developing
celiac disease are referred to as potential celiac disease patients. However, these patients are not
treated. This review highlights that patients with normal biopsies may suffer from the same
extra-intestinal gluten-induced complications before the disease manifests at the intestinal level.
We discuss diagnostic markers revealing true potential celiac disease. The evidence-based medical
literature shows that these potential patients, who are “excluded” for celiac disease would in fact
benefit from gluten-free diets. The question is why wait for an end-stage disease to occur when
it can be prevented? We utilize research on dermatitis herpetiformis, which is a model disease
in which a gluten-induced entity erupts in the skin irrespective of the state of the small intestinal
mucosal morphology. Furthermore, gluten ataxia can be categorized as its own entity. The other
extra-intestinal manifestations occurring in celiac disease are also found at the latent disease stage.
Consequently, patients with celiac traits should be identified and treated.
Keywords: gluten; latent celiac disease; potential celiac disease; extra-intestinal manifestations; mild
enteropathy; early developing celiac disease; genetic gluten intolerance; natural history; celiac trait
1. Introduction
Celiac disease is an autoimmune systemic disorder in genetically susceptible persons perpetuated
by the daily ingestion of gluten cereals (wheat, rye, and barley) with manifestations in the small
intestine and organs outside the gut. Patients diagnosed with celiac disease show gluten-induced and
gluten-dependent duodenal mucosal lesions (i.e., the typical crypt hyperplastic lesion with villous
atrophy). Clinically these newly diagnosed patients may or may not be suffering from gastrointestinal
symptoms. A gluten-driven extra-intestinal manifestation is often the only clue for the disease. In the
primary care and within different medical disciplines, physicians should suspect celiac disease and
perform case finding by serum autoantibody screening. Positive serology is often the only way to
identify potential patients for a diagnostic upper intestinal endoscopy [1–3]. In fact, less than half of
all adult patients diagnosed with celiac disease complain of gastrointestinal symptoms at an initial
diagnosis [4]. This knowledge comes from Finland, where adult celiac disease diagnoses have increased
20 times in recent decades and 0.8% of the total population has a biopsy-confirmed diagnosis [5–7].
Patients diagnosed with celiac disease including a duodenal mucosal lesion may suffer from
a number of extra-intestinal diseases [2,3]. Dermatitis herpetiformis manifests outside the gut, is
gluten driven and dependent [8,9], has the same genetic background, and occurs within the same
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families as celiac disease [9,10]. In fact, one identical twin may have celiac disease while the other
suffers from dermatitis herpetiformis [11]. Other gluten-driven extra-intestinal manifestations in celiac
disease include osteopenia, osteoporosis, fractures [12–14], permanent tooth enamel defects [6,15],
arthritis, and arthralgia [16–18] as well as further central and peripheral nervous system [19–22],
liver [23–25], and reproductive system involvements [26,27]. Even autoimmune diseases may be gluten
driven [28,29], and there is a risk for malignant complications, especially non-Hodgkin lymphoma, in
untreated celiac disease [30,31].
By definition, celiac disease is excluded in patients who have normal small intestinal mucosal
morphology at their first diagnostic endoscopy if they have been following a normal gluten-containing
diet. However, it seems evident that this is not accurate. In a review in 2001, we wrote that
gluten-induced extra-intestinal manifestations may develop at the latent disease stage when the
mucosa is still morphologically normal [32], citing several observations [19,33–36]. Today such patients
are often referred to as having “potential celiac disease” because they are found to be “normal” on
biopsy [37]. Meanwhile, dermatitis herpetiformis is our model disease, in which an extra-intestinal
manifestation is treated with a gluten-free diet irrespective of the mucosal finding (diseased or not).
We reviewed the literature for evidence for extra-intestinal gluten-dependent manifestations in patients
“excluded” for celiac disease. In this paper, we also discuss tools for identifying these “potential”
treatable patients.
2. Latent or Potential Celiac Disease
The “pre-celiac” state has been described in patients with dermatitis herpetiformis, in whom
small intestinal mucosal deterioration was shown to occur after adding extra gluten to the diet [38–40].
An extra gluten load also induced mucosal lesions in healthy individuals [39,41]. The concept of latent
celiac disease, without having an extra load of gluten, was shown to be part of the gluten sensitivity
spectrum and natural history of celiac disease [42–45]. Specifically, this was shown in Finland in celiac
patients who, by chance, had previously undergone a small intestinal biopsy that was reported as
normal or who were followed up because of positive serum autoantibody results.
We chose to use the term “latent celiac disease”, which is similar to Weinstein [38], when referring
to patients with a normal biopsy who later exhibited mucosal deterioration and were diagnosed as
celiac disease patients. For us, “latent” means existing but not manifest (i.e., the disease exists but is
not manifest at the mucosal level). Based on our early descriptions, Ferguson et al. (1993) defined
latent celiac disease as follows: “This term should only be applied to patients who fulfill the following
conditions: (i) have a normal jejunal biopsy while taking a normal diet, (ii) at some other time, before
or since, have had a flat jejunal biopsy which recovers on a gluten free diet” [46]. Following the first
reports on existing celiac disease latency, a numbers of other results have been published, with early
papers by Troncone [47] and Corazza et al. [48]. It is now clear that oral tolerance towards gluten can
be kept for longer periods, even for decades and into older age [49].
The term “potential celiac disease” has been used interchangeably with latent celiac disease,
and this has led to confusion in the celiac disease literature. Thus, the Oslo task force discouraged the
use of the term “latent celiac disease”, and individuals with a normal outcome from a small intestinal
biopsy but who are at increased risk of developing celiac disease based on positive celiac disease
serology should be referred to as having potential celiac disease [37]. These “potential patients” are
not treated as celiac. The question is, what should a gluten-triggered and gluten-dependent treatable
disease outside the gut be called, when the extra-intestinal manifestation occurs at the latent stage of
the disease and when conventional diagnostic biopsy criteria have excluded celiac disease? We infer
that such patients should not be categorized as having potential celiac disease. Rather, they require
proper treatment [50,51].
In Figure 1, we summarize the lifespan natural history of celiac gluten sensitivity, where each
line represents a single individual. The term celiac gluten sensitivity encompasses celiac traits, latent
celiac disease, genetic gluten intolerance, mild enteropathy celiac disease, early developing celiac
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disease, and celiac disease itself [1,32,50–53]. The gluten-induced mucosal damage develops rapidly
or gradually from normal mucosal morphology to a manifest mucosal lesion. The tolerance towards
gluten is individual, and it may be broken after only months or years (childhood celiac disease) but
also at adolescence, adulthood, and even after decades of gluten ingestion in old age. The latent celiac
disease patients, the “true potential” patients in Figure 1 (i.e., normal on biopsy showing villus height
crypt depth ratio >2), are classified as having celiac disease only when the disease has deteriorated to
the degree of a manifest mucosal lesion (i.e., villus height crypt depth ratio <2).
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celiac disease - includes in its definition the susceptibility genes for celiac disease and the genes 
encoding the human leukocyte antigen (HLA) DQ2 or DQ8 molecules [1,32,54]. This is a check that 
clinicians may perform when there are symptoms and signs suggestive of celiac disease, but the 
biopsy is normal or does not show clear crypt hyperplasia. It shows only inflammation and 
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develop. 
Patients positive for celiac disease serology with normal biopsies should be considered to have 
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celiac disease control patients and even in healthy individuals, does not correlate with celiac disease 
susceptibility genes [55]. Currently, tissue transglutaminase autoantibody (TG2-ab) testing is used to 
screen for celiac disease. It should be noted, however, that not all serum TG2-abs predict celiac disease 
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Figure 1. Natural history of developing celiac disea (CD) at the small intestinal mucosal level. Each
line repr sents one individual. We are born with a normal mucosal morphology, a villus height (VH),
and a crypt depth (CrD) ratio of approximately three and villi three times taller than crypts are deep.
Upon gluten ingestion, mucosal injury proceeds rapidly or gradually at different ages, in childhood or
only at an older age. Before developing a manifest ucosal lesion (diseased mucosa on biopsy, VH:CrD
<2) every CD patient belongs to the category latent “true potential” CD (normal on biopsy, VH:CrD >2).
3. Markers of Existing Early Disease
An existing gluten-dependent dis ase without evidence of enteropathy until a later age - latent
celiac disease - includes in its definition the susceptibility genes for celiac disease and the genes
encoding the human leukocyte antigen (HLA) DQ2 or DQ8 molecules [1,32,54]. This is a check that
clinicians may perform when there are symptoms and signs suggestive of celiac disease, but the biopsy
is normal or does not show clear crypt hyperplasia. It shows only inflammation and descriptive mild
villus atrophy. Positivity for DQ2 or DQ8 does not mean very much, since 30% to 40% of the citizens
in the country are positive, but double negative means that no celiac disease will develop.
Patients positive for celiac disease serology with normal biopsies should be considered to have
potential celiac disease [37]. However, gliadin antibody positivity, which is a frequent finding
in celiac disease control patients and even in healthy individuals, does not correlate with celiac
disease susceptibility genes [55]. Currently, tissue transglutaminase autoantibody (TG2-ab) testing
is used to screen for celiac disease. It should be noted, however, that not all serum TG2-abs
predict celiac disease [56]. TG2-abs have been described in other autoimmune diseases as well
as in infections, tumors, myocardial damage, liver disorders, and psoriasis [54]. These antibodies
are not associated with endomysial autoantibodies and may occur in persons negative both for HLA
DQ2 and DQ8. The serum endomysial antibody test is the gold standard, and the presence of these
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autoantibodies predicts impending celiac disease [1,45,50,53,55]. In celiac disease in patients with
extra-intestinal manifestations, other autoantibodies play a role in diagnosis and potentially in disease
mechanisms [57].
At the mucosal level, inflammation, as measured as the density of intraepithelial T cells
(IELs), is a very unspecific finding, but is also gluten-dependent in cases of celiac disease [58].
Marsh 1 lesions with increased IELs were shown to have a sensitivity of 59% and specificity of
57% in predicting forthcoming celiac disease [59]. However, when searched for, an autoimmune
insult to the morphologically normal intestinal mucosa is, in fact, present. A high density of γδ
T-cell-receptor-bearing IELs in patients with morphologically normal mucosa who also carry the
susceptibility genes for celiac disease seems to be a prerequisite for developing celiac disease [43,60,61].
Yet, even if an increased density of γδ T cells is found in latent celiac disease, such a finding is not
pathognomonic for the disease [59,61]. In the small intestine, the gluten-dependent autoantibodies
target extracellular TG2 and may be detected as IgA deposits in biopsy tissues at the latent disease
stage [62–64] (Figure 2). In fact, the IgA deposits in the duodenal biopsies accurately predicted
forthcoming celiac disease better than IELs, γδ+ IELs, or serum autoantibodies [59]. The detection
of intestinal TG2-abs by phage-antibody libraries is another possibility for diagnosis [52]. However,
intestinal TG2-ab production is not only found in celiac disease [65]. Again, when finding an increased
density of γδ+ IELs or IgA deposits in a patient with normal small intestinal mucosal morphology, it is
recommended to check whether the patient belongs to the “celiac family” (i.e., are carrying either the
HLA DQ2 or DQ8 molecules).
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4. Extraintestinal Manifestations
4.1. Dermatitis Herpetiformis
In dermatitis herpetiformis, a gluten-induced and gluten-dependent manifestation occurs outside
the gut even in the absence of intestinal mucosal villous atrophy [8,66]. Today, up to 30% of patients
with dermatitis herpetiformis have a normal small intestinal mucosal lining [67]. Typically, the disease
manifests with itchy papules and vesicles on the elbows, knees and buttocks, and overt gastrointestinal
symptoms are rare [67,68]. When patients without enteropathy are challenged with extra gluten, their
small intestinal mucosae deteriorate in a way typical of celiac disease [38–40]. When no enteropathy is
present, patients only test positively for serum TG2-abs and endomysial antibodies in 40% of cases [67].
However, the patients could be serum endomysial autoantibody positive already while having normal
small intestinal mucosa prior to any evidence of skin eruptions [44]. If searched for, the autoimmune
effect to the morphologically normal intestinal mucosa caused by an environmental trigger—the daily
ingestion of gluten—is, in fact, present. Mucosal inflammatory markers (i.e., the high density of
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γδ+ IELs) shows this [35]. Furthermore, in patients who are negative for serum autoantibodies, the
antibodies are found at the mucosal level targeting extracellular TG2 [62,69,70], which is a finding
typical for an existing disease that is not manifest at the mucosal architectural level (Figure 2).
We infer that patients with gluten-triggered extra-intestinal manifestations, who are now classified
as having dermatitis herpetiformis but show a normal small intestinal mucosa, do not belong to the
category of potential celiac disease. These patients may even be suffering from osteoporosis and
experience bone fractures. Clearly, it is a treatable disease [67,68,71]. In the following, we use parallel
reasoning for patients having other gluten-dependent extra-intestinal manifestations occurring at the
latent stage of celiac disease.
4.2. Central and Peripheral Nervous System
Gluten-induced neurological manifestations including gluten ataxia are common in adult celiac
disease [19–22] and occur in children [2]. Hadjivassiliou et al. noticed that gluten sensitivity was found
in patients with neurological disease, and they screened the patients with gliadin antibodies [72]. They
also showed that neurological complications occurred during the latent stage of celiac disease. Their use
of gliadin antibodies created some skepticism toward the findings, but today gluten ataxia has become
a gluten-induced entity in itself, similar to dermatitis herpetiformis [20,73]. In fact, it was shown that
gluten ataxia might respond to a strict gluten-free diet even in the absence of an enteropathy [74,75].
Serum transglutaminase 6 antibodies are used for detecting gluten ataxia in patients with and without
small intestinal mucosal lesions. Negative seroconversion results from a gluten-free diet [75]. Further
evidence that gluten ataxia without enteropathy belongs to the celiac spectrum comes from the finding
that TG2-specific autoantibody deposits were detected in the intestinal mucosa [74]. The patients were
HLA DQ2-positive or DQ8-positive. All of the control ataxia patients were negative for celiac-type HLA,
and they had no IgA deposits in the mucosa [74]. In one gluten ataxia patient, similar TG2-targeted
IgA deposits were found in the small vessels of the brain [74]. In a different cohort of idiopathic
ataxia patients, the TG2-targeted IgA deposits were again detected, even in the absence of circulating
TG2-abs [76].
Gluten-induced peripheral nervous system involvement often expresses as a symmetrical
sensorimotor axonal peripheral neuropathy [77]. In patients with or without enteropathy, neuropathies
cannot be differentiated based on clinical, genetic, or immunological grounds [78,79].
4.3. Bone Disease
Bone diseases, osteopenia, osteoporosis, and even fractures are highly prevalent in untreated
celiac disease [14,80,81]. Strict gluten-free diets improve bone health in celiac disease and are an
effective therapy for long-term bone mineral recovery [13,82].
Latent celiac disease patients, before manifesting an overt disease, might suffer from
gluten-dependent symptoms as well as osteopenia and osteoporosis [62,83–86]. Kaukinen et al. showed
that eight of 10 patients without villous atrophy had a bone disease, and they all were DQ2 positive [83].
On biopsy, it was shown that they belonged to the celiac spectrum since they had increased densities
of γδ+ IELs. Furthermore, their initial TG2 and endomysial antibodies normalized with a gluten-free
diet. Dickey et al. again measured bone mineral density in 31 endomysial antibody-positive patients
who were excluded for celiac disease (i.e., classified as having Marsh 0 or Marsh 1 lesions). They
found osteopenia to be present in 30% and osteoporosis in 10% of these patients, and the degree of
bone disease did not differ from that found in patients diagnosed with overt celiac disease. Negative
seroconversion followed upon implementation of a gluten-free diet in the 26 of the 27 patients with
normal biopsies. On the contrary, eight patients continued their gluten-containing diet, and seven
of them evolved toward villous atrophy compatible with celiac disease within one to two years [84].
Kurppa et al. proved that the gluten-free diet had a positive effect on the bone mineral density in
endomysial antibody-positive patients with normal villous morphology, which is similar to those with
celiac-type enteropathy [85]. Zanini et al. concluded that celiac disease patients with mild enteropathy
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have various markers of existing malabsorption including bone disease, and, thus, require treatment
with a gluten-free diet [86].
Patients with true potential celiac disease are also a risk of fractures. Pasternack et al. showed
that dermatitis herpetiformis patients reported earlier fractures in 45 out of 222 cases at diagnosis.
Altogether, 16% of the fractures had occurred in patients with normal small intestinal histology, 35%
occurred in patients with partial villous atrophy, and 49% occurred in patients with subtotal villous
atrophy in Reference [71].
4.4. Liver Diseases
Celiac disease may initially present as a monosymptomatic liver disease, such as cryptogenic
hypertransaminasaemia or autoimmunue-type of liver damage [23–25,87]. There are few reports of
liver injury in potential or latent celiac disease. Zanini et al. observed that celiac disease with mild
enteropathy and positive celiac disease-related serology is not a mild disease. Moreover, they showed
alanine aminotransferase serum values to be elevated in 9/121 (8%), γ-glutamyltransferase in 5/102
(5%), and alkaline phosphatase in 6/101 (6%) of patients. The authors concluded that these patients
should also be treated [86].
4.5. Other Extraintestinal Manifestations
4.5.1. Permanent Tooth Dental Enamel Defects
Adult patients with celiac disease and dermatitis herpetiformis, as well as children with dermatitis
herpetiformis, show celiac-type dental enamel defects in their permanent dentition [15,88–90]. Typical
enamel defects were found in all healthy family members of celiac disease patients found to have
manifest mucosal lesions. Furthermore, these celiac-type enamel defects occurred without small
intestinal changes and were strongly associated with the HLA DR3 [34]. Importantly, these permanent
tooth enamel defects are induced by gluten ingestion in early childhood, when the enamel is developing
(i.e., at the latent stage of celiac disease and dermatitis herpetiformis).
4.5.2. Malignancies
In 1986, Freeman and Chiu reported that intestinal lymphoma might appear at the latent stage of
celiac disease when the mucosa is morphologically normal [33]. However, it is not known whether
untreated patients without a manifest mucosal lesion carry an increased risk of malignancy. However,
there are many complications, including malignancies, that may occur in adulthood when the patient
is undiagnosed by ingesting gluten. Celiac disease patients diagnosed at an adult and elderly age have
not had manifest mucosal lesions from early childhood (Figure 1) [42–45,48,49].
Figure 3 indicates that all the extra-intestinal manifestations induced by gluten in untreated celiac
disease can be detected in the latent stage of the disease.
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Figure 3. Celiac trait. Gluten-induced extra-intestinal manifestations exist in both patients with normal
(latent celiac disease, CD) and diseased small intestinal mucosa (overt CD). Drawing adapted from the
“cooking pot” of splashing extra-intestinal manifestations, which is first presented at the International
Celiac Disease Symposium in Dublin 1992, and from drawings in references No. 34, 53, and 54.
5. Celiac Trait
Celiac disease diagnosis requires a gluten-induced small intestinal mucosal lesion. As indicated
in Figure 3, the so-called “flat” lesion is the end stage of the mucosal injury. Figure 3 also summarizes
our review and shows that, when there is a gluten-induced and gluten-dependent extra-intestinal
manifestation in celiac disease, the manifestation can be found in patients before the mucosa is
diseased or when it shows only minor non-specific changes. For susceptible persons, upon gluten
ingestion, celiac disease develops gradually from normal mucosal morphology through mucosal
inflammation, crypt hyperplasia, and villous atrophy to the “flat” mucosal lesions [91]. When the
mucosa is morphologically normal and, for example, bones are already fracturing due to gluten
ingestion, we should not call this condition potential celiac disease [38]. Moreover, we should not wait
for the manifest mucosal lesion to develop (i.e., celiac disease). The patient deserves accurate treatment
early. The benefit of treating these patients may be due to correction of micronutrient deficiencies
having an impact on extra-intestinal manifestations [58]. We suggest that the term celiac trait be used
in these cases [1,32,51].
Author Contribu ions: Both authors searched the literature and contributed equally in writing the review.
F nding: A.P. and M.M. were financially supported by the Competitive State Research Fina cing of the Expert
Responsibility Area of Tampere University Hospital, Grant No. 9V041.
Conflicts of Interest: The authors declare no conflict of interest.
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